Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

• Status: Unknown status
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI) patients receiving percutaneous coronary intervention.

2. Ticagrelor can reduce the serum levels of inflammatory biomarkers both in coronary and in peripheral venous in patients with ST-segment elevation myocardial infarction(STEMI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jinan Central Hospital
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

1. Male or non-pregnant female.

2. Age ≥ 18 years old and <80 years old.

3. Consecutive patients who should be hospitalized with documented evidence of ST-Segment Elevation Myocardial Infarction receiving Percutaneous Coronary Intervention.

4. All patients havepersistent≥0.2 Millivolt ST segment elevation in two or more contiguous precordial leads or ≥0.1 Millivolt ST elevation in two or more contiguous limb leads, with one of the following: persistent chest pain or elevatory of biomarkers of myocardial necrosis.

5. Time from chest pain onset to receiving Percutaneous Coronary Intervention <12 hours.

6. Persistent chest pain <12 hours.

7. Provision of informed consent prior to any study specific procedures.

Exclusion Criteria:

1. Involved in other trials.

2. In recent one year have P 2 Y 12 receptor antagonist drug treatment history or long-term use of immunosuppressive agents.

3. Recurrent myocardial infarction or previous history of Coronary Artery Bypass Graft(CABG) surgery or rescue Percutaneous Coronary Intervention.

4. Active bleeding or bleeding history.

5. With obvious infection and body temperature (axillary temperature) higher than 38.0 ℃.

6. Autoimmune diseases.

7. Malignancies.

8. In recent 6 months have received major surgery.

9. Left ventricular ejection fraction is less than 30%.

10. Life expectancy less than one year.

11. With moderate and severe liver function deterioration.

12. End-stage renal failure.

13. Other conditions that may put the patient at risk or influence study results in the investigators' opinion：eg, increased risk of bradycardiac events; known clinically important thrombocytopenia; known clinically important anemia; severe hemodynamic instability.

14. Other contraindications to investigate products.

15. Any condition that increases the risk for noncompliance or being lost to follow-up.